# Bio­phar­ma M&A is hav­ing one of its best stretch­es in years.

*business · news · 2026-04-09 · Endpoints News*

## Key points

- Bio­phar­ma M&A activity is currently experiencing one of its strongest periods in years.
- Big pharma companies are increasingly acquiring smaller biotech firms in recent deals.
- The definition of a 'big' deal in biopharma M&A has shifted compared to previous years.
- Cash returns to investors from these deals are impacting the startup biotech market.

**Companies:** Barclays
**Countries:** United States

[Read the full story on Endpoints News](https://endpoints.news/post-hoc-live-biopharma-ma-is-back-with-barclays-emily-field/)

---

Canonical: https://newsio.io/n/775adc18-9757-4ce6-bc25-10f91d4f923e/biopharma-ma-is-having-one-of-its-best-stretches-in-years
Summarized by Newsio from Endpoints News. https://newsio.io/how-it-works